Biomedical subjects

P Hüppi

Publications and source records attributed to P Hüppi.

21 records · Page 2Linked to original sources

PubMedDate not supplied

[Neurosonography and creatine kinase BB level in premature infants with perinatal risk factors].

High-resolution real time ultrasound scan is used for early diagnosis of PIVH in neonates. Furthermore, in term infants an increase of serum Creatine-Kinase BB (CK-BB) values has been found to be clinically useful for diagnosis and prognosis of several perinatal cerebrovascular injuries. Eighty-eight preterm infants with different grades of PIVH (I-IV) were studied by serial measurements of CK-BB levels in serum. No statistical correlation was found between enzymatic levels, severity of PIVH and perinatal risk factors (p greater than 0.5).

Brain Damage, Chronic↗

PubMedDate not supplied

[Prenatal and postnatal determination of gestational age of small newborn infants].

Low birth weight infants are a heterogenous group of babies with medical risks that may vary according to gestational age. The degree of prematurity should be assessed using non-invasive valid methods. The purpose of this study was to assess the validity of four most commonly used methods for the assessment of gestational age in two groups of 60 appropriate for date pre-terms and 29 small for date babies. Our results support the use of prenatal assessment of gestational age by maternal history and early ultrasonography in afd-infants, the use of the examination of the anterior vascular capsule of the lens in afd and sfd infants and physical criteria rather than neurologic criteria when using the Ballard score.

Adolescent↗

PubMedDate not supplied

Prevention of symptomatic patent ductus arteriosus with ethamsylate in babies treated with exogenous surfactant.

Some trials in premature infants with respiratory distress syndrome have shown an increased incidence of patent ductus arteriosus after exogenous surfactant therapy. The effect of prophylactic ethamsylate on patent ductus arteriosus after intratracheal administration of a single dose of porcine surfactant preparation (Curosurf, 2.5 ml/kg) was studied in a group of 20 preterm infants with severe respiratory distress syndrome. Gestational age of the patients was 29.2 +/- 2.5 weeks (mean +/- SD), and birth weight was 1158 +/- 319 gm. Ethamsylate (12.5 mg/kg) was given prophylactically within the first 4 hours of life followed by 6-hourly doses for 4 days. Hemodynamically significant patent ductus arteriosus occurred more frequently in the untreated group (8 of 10) than in the ethamsylate group (2 of 10) (p < 0.02). No acute adverse effects were attributed to the therapy. This preliminary experience suggests that ethamsylate, an inhibitor of prostaglandin biosynthesis, could be useful in reducing the incidence of patent ductus arteriosus in very low birth weight infants treated with exogenous surfactant.

Biological Products↗